Business, energy, technology, markets and global industry news from Business News Today

Regeneron Pharmaceuticals

PharmaDeviceNews Regeneron Pharmaceuticals
Representative image of a clinician reviewing skeletal imaging, illustrating Mirum Pharmaceuticals and Incyte’s zilurgisertib Phase 2 progress in fibrodysplasia ossificans progressiva and the rare disease treatment questions facing regulators.
Pharma & Biotech

Mirum’s ATEBRIOZ reduced abnormal bone volume in young children, but will the FDA expand its approval?

Mirum's ATEBRIOZ reduced abnormal bone volume in children aged 6 to under 12 with FOP. Can the results support FDA label expansion in 2027?

Read More
A representative image illustrating Regeneron Pharmaceuticals’ Pasatru approval as the FDA clears the new fibrodysplasia ossificans progressiva treatment after Phase 3 data showed a 90% reduction in new heterotopic ossification lesions.
Pharma & Biotech

Can āshibio’s andecaliximab stop abnormal bone growth? An 86.2% flare-up reduction raises the stakes

āshibio reports 86.2% fewer FOP flare-ups with andecaliximab in early data, but placebo-controlled evidence remains pending.

Read More
Roche’s Susvimo uses the refillable Contivue eye implant to continuously deliver ranibizumab and reduce treatment frequency for wet age-related macular degeneration. Representative image.
Pharma & Biotech

Roche wins EU approval for Susvimo as wet AMD treatment burden becomes the next battleground

The European Commission has approved Roche’s Susvimo implant for neovascular age-related macular degeneration, offering continuous ranibizumab delivery with refills every six months and creating a fundamentally different alternative to repeated eye injections.

Read More
FDA approval gives adults with fibrodysplasia ossificans progressiva another treatment option after the OPTIMA study recorded just one to two new bone lesions with Pasatru versus 19 with placebo over 56 weeks. Representative image.
Pharma & Biotech

From a difficult Phase 2 to FDA approval: how Regeneron rebuilt its garetosmab FOP programme

FDA approval gives adults with fibrodysplasia ossificans progressiva another treatment option after OPTIMA recorded just one to two new bone lesions with Pasatru versus 19 with placebo over 56 weeks.

Read More
A representative image illustrating Regeneron Pharmaceuticals’ Pasatru approval as the FDA clears the new fibrodysplasia ossificans progressiva treatment after Phase 3 data showed a 90% reduction in new heterotopic ossification lesions.
Pharma & Biotech

FDA clears monthly Pasatru after Phase 3 data show sharp drop in abnormal bone formation

FDA approves Regeneron’s Pasatru after Phase 3 data showed a 90% reduction in new FOP bone lesions. See what the new therapy means.

Read More
Pharma & Biotech

Regeneron’s cemdisiran enters FDA and EMA review for generalized myasthenia gravis

Find out how Regeneron’s cemdisiran review could reshape generalized myasthenia gravis care with potential quarterly subcutaneous dosing.

Read More
Representative image of oncology drug discovery as Parabilis Medicines’ IPO surge puts Helicon peptides, zolucatetide, desmoid tumors, and Wnt-driven cancer treatment under sharper focus.
Pharma & Biotech

Parabilis Medicines IPO boom raises the bar for zolucatetide clinical execution

Find out how Parabilis Medicines’ IPO surge could reshape investor appetite for Helicon peptides and Wnt-driven oncology drugs.

Read More
Pharma & Biotech

Regeneron’s $2.2bn Parabilis pact signals rising interest in next-generation conjugates

ADCs changed cancer delivery. Regeneron and Parabilis now want Helicon peptides to push conjugates inside harder-to-drug biology.

Read More
Pharma & Biotech

Can Regeneron Pharmaceuticals redefine allergy treatment with Phase 3 allergen-blocking antibodies and Dupilumab expansion

Find out how Regeneron Pharmaceuticals’ AAAAI 2026 data could reshape allergy treatment strategies and regulatory expectations.

Read More